The USPTO issued Patent US12590307B2 to Arnatar Therapeutics, Inc. on March 31, 2026, covering ACT-UP1 compounds and methods for enhancing gene expression. The 21 granted claims relate to antisense oligonucleotide compounds coupled to translation-upregulation mechanisms for therapeutic applications. CPC classifications indicate coverage across nucleic acid compositions (C12N 15/113), pharmaceutical formulations (A61K 9/0019), and therapeutic uses (A61P 1/16). The technology has applications for treating diseases associated with gene expression dysregulation.

Pharmaceutical and biotechnology companies developing gene expression enhancement technologies, antisense oligonucleotides, or nucleic acid-based therapeutics should conduct freedom-to-operate analyses to assess potential infringement risks. Since this is a patent grant rather than a regulatory rule, no compliance actions are required, but entities should evaluate licensing opportunities or design-around strategies if their programs overlap with the 21 granted claims.